TUG

Sight from ... Sound

Glaucoma

More than 76 million cases in 2020 Estimated 112 million cases by 2040

28% increase of primary open-angle glaucoma in the US per decade to approximately 7.32 million by 2050

50% of persons with early stage glaucoma are unaware that they have the disease

$5.5 billion = Estimated annual US Glaucoma health care budget

#1 Cause of Irreversible Blindness Worldwide

Breakthrough Therapy

• One Time, 10 Minute Treatment

• No Pressure Spikes, Well Tolerated

• Replace or Supplement Medications

• Neuroprotection Of The Optic Nerve

Treated eyes show an increased thickness of the Retinal Nerve Fiber Layer

4 of 5

Delivering an Effective Solution

Comparable results to SLT for treatment with patients currently on medications.

80% of treatment naïve patients had ≥ 20% IOP reduction from baseline at 12 month follow-up.

• Use for all glaucoma variants

• Minimal equipment required

• Non-invasive / Ab externo

Meet Our Team

EyeSonix's team strives to extend "sighted life" worldwide by making available a simple and highly effective glaucoma treatment, breaking the paradigm of present day glaucoma care.

DONALD SCHWARTZ, OD, MD

President and Founder

ERIC SCHULTZ, MS

CEO, CTO and Co-Founder

OMID KHODAI, OD, MS

Clinical & Regulatory

SHARON BAKALASH, MD, PhD

Board Member

DALE HEUER, MD

Medical Advisor

VINCENT M. PATELLA, OD

Medical Advisor

BARRY SEIBEL, MD

Medical Advisor

JOHN SAMPLES, MD

Medical Advisor

ALAN ROBIN, MD

Clinical Advisor

JAGDEEP KAKADIA, MD, PhD

Medical Advisor

DARYL MICHALIK, MBA

Business Development

TOSIN SMITH, MD

Medical Advisor

STEPHANIE KAPLAN, MBA

Operations & Quality

DAVID RICHARDSON, MD

Medical Advisor

RAMESH SHAH, MD

Medical Advisor

Contact Us

If you're interested in hearing more about the technology, have a business proposal, or are interested in making a purchase, we'd love to hear from you.